The telehealth-consultation platform said it plans to continue expanding its weight loss offerings.

Hims & Hers Health (NYSE:HIMS) stock gains as the company adds Eli Lilly's (LLY) weight loss therapy tirzepatide & generic ...

Hims & Hers Health shares jumped Tuesday as the company added Eli Lilly’s weight-loss drug Zepbound and diabetes treatment ...

Meanwhile, the first major obesity-related phase 3 trial for orforglipron is set to complete in July. If the data from the ...

Eli Lilly sues two compounders over tirzepatide after FDA lifts Zepbound, Mounjaro shortage status in key GLP-1 legal test.

Eli Lilly ( NYSE: LLY) on Tuesday will file lawsuits against two companies that the drug giant is accusing of mass ...

Eli Lilly is suing Strive Pharmacy and Empower Pharmacy for compounding tirzepatide, the active ingredient in Zepbound and ...

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...

Eli Lilly quickly disassociated itself from Hims & Hers after the telehealth company said it was selling the pharmaceutical ...

Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's diabetes and weight-loss drugs on its ...

Eli Lilly (LLY) is taking legal action against makers of off-brand versions of its blockbuster diabetes and weight-loss drugs ...

Eli Lilly (LLY) is targeting additional drug compounders and telehealth companies that make copycat versions of its weight loss drug, with ...